Physician profile
Erick Torres
NPI 1104457621
$2,074.63
in general payments reported to CMS, 2019-2025
22 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $912 · 2023: $261 · 2024: $271 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.71 | 2022-2024 | |
| Glaxosmithkline, LLC. | $235.76 | 2022 | |
| Boston Scientific Corporation | $205.86 | 2022-2023 | Superion Indirect Decompression System, Watchman Flx |
| Abbvie INC. | $170.27 | 2021-2023 | |
| Exact Sciences Corporation | $170.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $163.82 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.85 | 2021-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $121.83 | 2022 | |
| Madrigal Pharmaceuticals | $115.33 | 2025 | Rezdiffra |
| Sanofi Pasteur INC. | $78.07 | 2021-2025 | |
| Pfizer INC. | $76.38 | 2022-2024 | |
| Lucid Diagnostics INC. | $71.40 | 2022-2023 | |
| Amgen INC. | $64.45 | 2021-2024 | Otezla, Repatha |
| Recordati_rare_diseases_inc. | $34.82 | 2024-2025 | Isturisa, Signifor Lar |
| Redhill Biopharma INC. | $33.04 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.51 | 2021-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $24.27 | 2022 | |
| Qiagen, LLC | $20.35 | 2025 | |
| Corcept Therapeutics | $16.64 | 2025 | Korlym |
| Cranial Technologies, INC | $14.94 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $13.83 | 2023 | Rotateq, Vaqta, Gardasil 9 |
| Arbor Pharmaceuticals, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.